Abveris is a premium contract research organization that uses genetically engineered in vivo systems for the discovery of antibodies in tight timelines. Our discovery platform is anchored on an proprietary uses proprietary mice, Diversimab, that have been engineered to express a more diverse antibody repertoire than wild-type mice. The limiting factor in most in-vivo antibody discovery platforms is the diversity of the immune response of the host animal. We deliver antibodies to targets, and individual epitopes on those targets, that cannot be found in natural in vivo systems. This enables the discovery of antibodies with specificities that cannot be found in other in-vivo systems. To streamline antibody screening from upstream hit generation, a wide range of screening methods and assay development capabilities have been developed in-house in Abveris. When well-designed screening methods are applied to the large panel of hybridomas discovered, optimal antibodies are delivered. Abveris’s platform can deliver antibody candidates with desired affinity, specificity, and epitopic coverage in industry-leading timelines.
Abveris's offering is differentiated in the followings:
ELISA for primary antibody hit screening
Royalty/milestone free, rapid delivery and you can expect antibodies to novel epitopes.
Single B Cell Screening
Using an in-house developed and optimized Single B Cell Screening Workflow based on Berkeley Lights' Beacon system for rapid antibody discovery.
Plasma B Cell Screening
Panels of custom-screened mAbs delivered against a wide variety of target types. Difficult targets are welcome.
Industry-leading sequence-to-sequence delivery timeline
Biomolecular Interaction Analysis Services
Abveris, Inc has not received any reviews.
Abveris, Inc has not received any endorsements.